Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is an open label, single center, non-randomized dose de-escalation phase I study of
combination of BV and Mogamulizumab.
The primary objective of the study is to assess the safety and tolerability of the
combination. The primary objective is also to explore safe dose of combination for future
expansion.